# Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

> **NCT02607813** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 142 (actual)

## Conditions studied

- NSCLC
- Ovarian Cancer
- Melanoma
- Other Solid Tumors

## Interventions

- **DRUG:** LXH254
- **DRUG:** PDR001

## Key facts

- **NCT ID:** NCT02607813
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01-18
- **Primary completion:** 2022-02-18
- **Final completion:** 2022-02-19
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2022-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02607813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02607813, "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02607813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*